TP53 and non-small cell lung carcinoma: Given that PCs reduce cellular growth and proliferation in NSCLC cells via upregulating p53 expression, targeting such natural compound in treatment regimes might help in downregulating cellular signaling pathways, as the mechanisms involved in Aβ-induced proliferation and anti-apoptosis in NSCLC cells.